THBS1 and neoplasm: High-risk ARGs (e.g., CBS, CD36) correlate with poor survival in OS. Anti-CD36 therapies targeting TSP-1/CD36 loops reduce angiogenesis and tumor growth; identified drugs (e.g., Bortezomib, Sunitinib) show potential.